Boston Common Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Boston Common Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-327,410	Closed	-$10.9M	–	195
2017 Q2	$10.9M	Buy	327,410 +96,110	+42%	+$2.97M	1.43%	15
2017 Q1	$7.42M	Sell	231,300 -30,645	-12%	-$1.05M	1.01%	28
2016 Q4	$9.5M	Buy	261,945 +74,990	+40%	+$2.99M	1.39%	17
2016 Q3	$8.6M	Sell	186,955 -1,720	-0.9%	-$89.7K	0.47%	76
2016 Q2	$9.48M	Sell	188,675 -3,370	-2%	-$179K	0.54%	73
2016 Q1	$10.3M	Buy	+192,045	New	+$11.3M	0.58%	71

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Boston Common Asset Management's TEVA Position: Q3 2017 in Review

Boston Common Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 327,410 shares — an estimated $10.9M sold.

Boston Common Asset Management first reported a position in TEVA in Q1 2016 and held it in 6 quarters. The position peaked at $10.9M in Q2 2017. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Boston Common Asset Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Boston Common Asset Management sold 327,410 Teva Pharmaceuticals shares in Q3 2017, an estimated $10.9M.
Boston Common Asset Management first reported a position in Teva Pharmaceuticals in Q1 2016 and held it in 6 quarters.
Boston Common Asset Management's Teva Pharmaceuticals position peaked at $10.9M in Q2 2017.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Boston Common Asset Management's 13F filing for Q3 2017, filed 13 Nov 2017.